These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3823092)

  • 1. Biochemical alterations produced by neuroleptics in man: studies of plasma homovanillic acid in schizophrenic patients.
    Pickar D; Wolkowitz OM; Labarca R; Doran AR; Breier A; Paul SM
    Psychopharmacol Ser; 1987; 3():248-54. PubMed ID: 3823092
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients.
    Pickar D; Labarca R; Linnoila M; Roy A; Hommer D; Everett D; Paul SM
    Science; 1984 Aug; 225(4665):954-7. PubMed ID: 6474162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with schizophrenia.
    Doran AR; Labarca R; Wolkowitz OM; Roy A; Douillet P; Pickar D
    Arch Gen Psychiatry; 1990 Jun; 47(6):558-63. PubMed ID: 2350208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma homovanillic acid as a predictor of response to fluphenazine treatment.
    Van Putten T; Marder SR; Aravagiri M; Chabert N; Mintz J
    Psychopharmacol Bull; 1989; 25(1):89-91. PubMed ID: 2772121
    [No Abstract]   [Full Text] [Related]  

  • 5. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.
    Pickar D; Labarca R; Doran AR; Wolkowitz OM; Roy A; Breier A; Linnoila M; Paul SM
    Arch Gen Psychiatry; 1986 Jul; 43(7):669-76. PubMed ID: 3718170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma homovanillic acid and other predictors of clozapine response.
    Pickar D
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():516A-517A. PubMed ID: 1498935
    [No Abstract]   [Full Text] [Related]  

  • 7. Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: correlations with CSF HVA.
    Doran AR; Rubinow DR; Wolkowitz OM; Roy A; Breier A; Pickar D
    Biol Psychiatry; 1989 Feb; 25(4):431-9. PubMed ID: 2564787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients.
    Konicki PE; Owen RR; Litman RE; Pickar D
    Life Sci; 1991; 48(14):1411-6. PubMed ID: 2008157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.
    Pickar D; Owen RR; Litman RE; Konicki E; Gutierrez R; Rapaport MH
    Arch Gen Psychiatry; 1992 May; 49(5):345-53. PubMed ID: 1375019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients.
    Davidson M; Kendler KS; Davis BM; Horvath TB; Mohs RC; Davis KL
    Psychiatry Res; 1985 Oct; 16(2):95-9. PubMed ID: 3865258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A central 6-hydroxydopamine lesion prevents fluphenazine-induced increase in plasma homovanillic acid.
    Labarca R; Thomas JW; Koulu M; Kim YS; Janowsky A; Wilkinson L; Linnoila M; Paul SM; Pickar D
    Brain Res Bull; 1988 May; 20(5):567-71. PubMed ID: 3133084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
    Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptics, dopamine, and schizophrenia.
    Pickar D
    Psychiatr Clin North Am; 1986 Mar; 9(1):35-48. PubMed ID: 2870480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma homovanillic acid as a predictor of response to neuroleptics.
    Davila R; Manero E; Zumarraga M; Andia I; Schweitzer JW; Friedhoff AJ
    Arch Gen Psychiatry; 1988 Jun; 45(6):564-7. PubMed ID: 3377643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of trifluoperazine on CSF and plasma HVA levels in schizophrenic subjects.
    Sharma R; Javaid JI; Janicak P; Comaty J; Davis JM; Faull K
    Am J Psychiatry; 1988 Nov; 145(11):1480-1. PubMed ID: 3189613
    [No Abstract]   [Full Text] [Related]  

  • 16. Persistence of cyclicity of the plasma dopamine metabolite, homovanillic acid, in neuroleptic treated schizophrenic patients.
    Davila R; Zumarraga M; Andia I; Friedhoff AJ
    Life Sci; 1989; 44(16):1117-21. PubMed ID: 2565009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma homovanillic acid concentration and the severity of schizophrenic illness.
    Davis KL; Davidson M; Mohs RC; Kendler KS; Davis BM; Johns CA; DeNigris Y; Horvath TB
    Science; 1985 Mar; 227(4694):1601-2. PubMed ID: 3975630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients.
    Suzuki E; Kanba S; Nibuya M; Adachi S; Sekiya U; Shintani F; Kinoshita N; Yagi G; Asai M
    Biol Psychiatry; 1994 Nov; 36(10):654-61. PubMed ID: 7880934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma HVA, neuroleptics, and dopaminergic plasticity.
    Dávila R
    Biol Psychiatry; 1989 Jan; 25(1):1-3. PubMed ID: 2563229
    [No Abstract]   [Full Text] [Related]  

  • 20. Schizophrenia: gender, family risk, and plasma homovanillic acid.
    Dávila R; Zumárraga M; González-Torres MA; Andía I; Zamalloa MI; Basterreche E; Guimón J; Friedhoff AJ
    Am J Med Genet; 1995 Apr; 60(2):154-6. PubMed ID: 7485251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.